Radius Health (RDUS) Misses Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Radius Health Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
February 25, 2016 6:30 AM ESTManagement to host conference call today at 7:30 am ET.Radius submitted an MAA in Europe for the investigational drug abaloparatide-SC for the potential treatment of postmenopausal osteoporosis and reduction of fracture risk on November 17, 2015. The application has been validated by the EMA and is currently under regulatory review. Radius is on track to submit an NDA for abaloparatide-SC in the U.S. at the end of the first quarter of 2016.
WALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (Nasdaq:... More
